Market's view on Synairgen
Published on April 2024
- Stock watcher shares experience of rebuying 100k shares at 6.6 after selling at 9.6, highlighting a significant trade based on anticipated news that the regulator might soon require.
- A stock watcher questions the intrinsic value of a patent, pondering if it could be sold, reflecting concerns about the company’s assets.
- Stock watcher expresses skepticism about past claims of high treatment costs, suggesting a significant change in the company’s positioning or market perception.